Previous 10 | Next 10 |
Plus Therapeutics (PSTV) is collaborating with Medidata, a unit of Dassault Systèmes (OTCPK:DASTY), to evaluate the use of its Synthetic Control Arm (SCA) solution in a planned phase 2 trial of Rhenium-186 NanoLiposome in recurrent glioblastoma, a type of brain cancer. The...
AUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced a partne...
AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will ...
AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hed...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Happy Friday, trader! We’re starting off the day with an overview of the biggest pre-market stock movers for today! Source: f11photo/Shutterstock.com Moving stocks this morning are earnings reports, Covid-19 ...
These Penny Stocks Climbed During Premarket, Here’s Why One of the best ways to stay ahead with penny stocks is to find the largest premarket gainers. While this is in no way the only strategy to use when trading penny stocks , it can be a major asset. Typically, premarket ga...
Licenses targeted interventional radiotherapeutics platform Worldwide exclusive rights obtained for patents and next-generation technology to deliver targeted, precision radiotherapeutics for solid organ cancers Initial IND submission for treatment of liver cancer pl...
2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and ...
IsoTherapeutics Group LLC to develop and supply cGMP grade Rhenium-186 isotope for Plus Therapeutics’ Rhenium-186 NanoLiposome ( 186 RNL) radiotherapeutic Plus Therapeutics completes technology transfer of analytical test methods with Piramal Pharma Solutions ...
Plus Therapeutics is a clinical-stage biotech focused on radiotherapeutics for patients with rare and difficult to treat cancers. CEO Dr. Marc Hedrick on Rhenium-186 NanoLiposome, clinical trials and its niche focus. Lean business model means less dilution. For further detai...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...